Swiss sign next vaccine agreement with AstraZeneca
AstraZeneca is a frontrunner in a Covid-19 vaccine development
Copyright 2020 The Associated Press. All Rights Reserved
Switzerland has signed an agreement with British pharmaceutical company AstraZeneca to pre-order up to 5.3 million doses of a Covid-19 vaccine that is currently under development.
“Given that it is still not clear which vaccines will ultimately prevail, the government is taking a diversified approach,”a statement said on FridayExternal link.
Switzerland has already inked a deal with United States biotech firm Moderna to secure early access to 4.5 million doses of its Covid-19 vaccine.
It has also confirmed its participation in the World Health Organization’s COVAX initiative aimed at ensuring equitable access to Covid-19 vaccines when they are approved.
“The Swiss public will therefore gain access to a further Covid-19 vaccine – provided it successfully passes the clinical trial phase and is approved by Swissmedic,” the statement said.
Europe involvement
The contract with AstraZeneca – and the Swedish government – is based on an agreement between the European Commission and AstraZeneca for the delivery of up to 400 million doses for Europe.
These doses can be ordered by individual states according to their population numbers and procured once the vaccine has been approved. Sweden will order doses for countries like Switzerland which is not a member of the EU but is a member of EFTA (European Free Trade Association) and resell them at no profit.
If approved, the vaccine will be delivered directly to Switzerland by AstraZeneca, which submitted an application for approval of its medicine to Swiss drug authority Swissmedic at the start of October. This was the first time that a drugmaker had presented a coronavirus vaccine for approval in Switzerland.
This content was published on
Swiss drug authority Swissmedic has begun evaluating the so-called “Covid-19 Vaccine AstraZeneca”. It is the first time that a drugmaker has presented a coronavirus vaccine for approval in Switzerland.
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
This content was published on
Switzerland confirms participation in WHO COVAX initiative aimed at ensuring equitable access to Covid-19 vaccines when they are approved.
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
This content was published on
It’s the question we all want an answer to: when will there be a vaccine against Covid-19? And how is fair access being negotiated?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.